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Unveiling the regulatory pathways maintaining hepatic stellate cells (HSC) in a quiescent (q) phenotype 
is essential to develop new therapeutic strategies to treat fibrogenic diseases. To uncover the miRNA-
mRNA regulatory interactions in qHSCs, HSCs were FACS-sorted from healthy livers and activated 
HSCs (aHSCs) were generated in vitro. MiRNA Taqman array analysis showed HSCs expressed a 
low number of miRNAs (n = 259), from which 47 were down-regulated and 212 up-regulated upon 
activation. Computational integration of miRNA and gene expression profiles revealed that 66% of 
qHSC-associated miRNAs correlated with more than 6 altered target mRNAs (17,28 ± 10,7 targets/
miRNA) whereas aHSC-associated miRNAs had an average of 1,49 targeted genes. Interestingly, 
interaction networks generated by miRNA-targeted genes in qHSCs were associated with key HSC 
activation processes. Next, selected miRNAs were validated in healthy and cirrhotic human livers and 
miR-192 was chosen for functional analysis. Down-regulation of miR-192 in HSCs was found to be an 
early event during fibrosis progression in mouse models of liver injury. Moreover, mimic assays for 
miR-192 in HSCs revealed its role in HSC activation, proliferation and migration. Together, these results 
uncover the importance of miRNAs in the maintenance of the qHSC phenotype and form the basis for 
understanding the regulatory networks in HSCs.
Quiescent hepatic stellate cells (qHSCs) are the major cell type responsible for the intrahepatic uptake, 
storage and secretion of vitamin A (retinoids). Moreover, they are the main regulators of the extracellu-
lar matrix (ECM) turnover within the space of Disse by expressing ECM proteins (mainly non-fibrillar 
ECM, collagen type III, IV and laminin) and by modulating the expression of metalloproteinases and 
their inhibitors. In response to fibrogenic stimuli HSCs activate and acquire a myofibroblast-like phe-
notype which is characterized by an aberrant production and deposition of ECM proteins potentially 
leading to liver fibrosis and resulting in the disruption of the vascular architecture1–3. While the cellu-
lar mechanisms underlying HSC activation have been extensively studied, the signals and regulatory 
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pathways involved in the maintenance of HSC quiescence have barely been addressed. Moreover, most 
studies have been conducted in rodent models of liver disease and little information is available on 
human HSCs.
miRNAs are small non-coding RNAs of approximately 22 nucleotides that act as post-transcriptional 
gene expression regulators by degrading target mRNAs through perfect complementarity of the miRNA 
with the 3’ untranslated region (3’UTR) of mRNA or by inhibiting translation if an imperfect base pair-
ing match exists4. Several miRNAs involved in HSC activation have been reported and their potential 
anti-fibrotic effects have been shown by inhibiting miRNAs function in vivo and in vitro5–7. One of the 
best studied miRNAs in HSCs is miR-21, which has been shown to be up-regulated in human and murine 
fibrotic liver samples. Indeed, knock down of miR-21 expression down-regulates the expression levels 
of COL1A1 and ACTA2 in primary HSCs. Furthermore, several miRNAs down-regulated during HSC 
activation have been suggested to play an anti-fibrogenic role8. That is the case for miR-150 and miR-
194 among others, which are significantly down-regulated in HSCs isolated from bile duct-ligated (BDL) 
compared to sham operated rats. Moreover, several studies have shown a significant down-regulation 
of miR-29 in fibrotic mouse livers and miR-29b up-regulation was shown to repress HSC activation by 
regulating collagen synthesis in primary human HSC cultures9,10. Although a limited number of miRNAs 
have been described in both quiescent and activated HSCs (aHSCs)8–12, no global miRNA analysis has 
been performed on qHSCs. Thus far, little is known about miRNAs expressed in human qHSCs and their 
potential functional role in promoting the maintenance of quiescence.
By integrating miRNA and gene-expression data obtained through the analysis of human qHSCs and 
their respective culture-activated counterparts we identified relevant miRNAs involved in the mainte-
nance of the quiescent phenotype of human HSCs. Moreover, the integrative analysis allowed us to iden-
tify miRNA-mRNA interaction networks potentially involved in HSC quiescence and activation. Finally, 
we have identified a panel of miRNAs with predicted target genes associated with HSC activation, and 
thus with a potential role in the repression of activation.
Methods
Patient samples. MiRNA and mRNA expression profiles were performed using HSCs and liver sinu-
soidal endothelial cells (LSECs) isolated from 4 cadaveric donors and 2 samples of hepatocytes obtained 
from two different donors. The protocol and conducted experiments were approved by the ethical 
committees of St-Luc Hospital and faculty of Medicine of Université Catholique de Louvain. An agree-
ment from the Belgian Ministry of Health was obtained for the hepatocytes and hepatic stem cell bank. 
MiRNA expression validation was performed on liver samples of 14 healthy subjects and 15 patients with 
cirrhosis with superimposed alcoholic hepatitis (AH). The healthy controls were selected as previously 
described13. The protocol was approved by the ethics committee of the Hospital Clinic of Barcelona. 
Informed consents and the protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki were given and signed for all the patients. Clinical features of the cadaveric donors used for HSC 
isolation and cirrhotic patients are summarized in Supplementary Table 1 and 2, respectively.
Isolation of high-purity qHSC and LSEC populations from healthy human livers. Human liver 
cells were isolated from the left liver segment of healthy donors up to 12 hours after clamping using a 
two-step perfusion technique14. Livers were kept on ice until sequential perfusion with an EGTA and 
digestion enzyme solution (0.9 mg/ml collagenase P and 0.03 mg/ml soybean trypsin inhibitor) was per-
formed. Parenchymal cells were removed by low-speed (50 g) centrifugation steps. Non-parenchymal 
cells were suspended in a 5% FBS, 2 mM EDTA buffer and incubated for 30 minutes at 4°C with anti-
bodies against CD32 (Abcam, Cambridge, United Kingdom) and CD45 (BD Biosciences, San Jose, CA) 
or with corresponding isotype controls. 7-aminoactinomycin D (eBioscience, San Diego, CA) was used 
to discriminate for non-viable cells. Enriched populations of human qHSCs were sorted out through a 
negative selection for CD32 (Ex: 488 nm; Em: 575 nm) and CD45 (Ex: 495 nm; Em: 519 nm) expressing 
cells and a positive selection for ultraviolet positivity (retinyl esters auto-fluorescence at 328 nm), using 
a fluorescence activated cell sorter (FACS-Aria BD Biosciences). Enriched populations of LSECs were 
obtained as CD32+CD45− cells. Purified populations of qHSCs and LSECs were immediately used for 
total cell RNA and miRNA extraction.
In vitro activation of human primary HSCs. Homogeneous populations of aHSCs were obtained 
as previously described15 by plating the cell fraction obtained by Nycodenz (Myegaard, Oslo, Norway) 
gradient centrifugation of the non-parenchymal cell fraction. Human aHSCs were cultured until passage 
four in Dulbecco’s modified Eagle’s medium (Lonza, Verviers, Belgium) supplemented with 10% fetal 
bovine serum (Biochrom GmbH, Berlin, Germany), at 37 °C in a humidified atmosphere with 5% CO2.
Purity of human liver cell populations. The purity of the FACS sorted cell populations and 
culture-activated HSCs was assessed by quantitative real time PCR for HSC quiescence (SPARCL1 and 
ATP1B2) and activation (ACTA2, COL1A1 and LOX) markers as well as the general HSC (PDGFRB), 
LSEC (CD32b), macrophage (F4/80) and hepatocyte (albumin) markers.
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Primary murine hepatic cells isolation. Male BALB/c mice (aged 20–25 weeks) were used and 
isolations were performed as described previously16,17. Briefly, after intraperitoneal anesthesia, the liver 
was perfused through the portal vein with buffers containing 0.25 mg/mL collagenase P (Roche Applied 
Science, Mannheim, Germany). Hepatocytes were separated from the non-parenchymal cell fraction by 
2 min centrifugation at 50 g. Viable hepatocytes were further purified by gradient centrifugation on a 
25% Percoll gradient (GE Healthcare Life Science, Diegem, Belgium). HSCs, LSECs and Kupffer cells 
(KCs) were collected from the non-parenchymal fraction by FACS (FACS Aria; Bectone Dickinson, 
Erembodegem, Belgium) using the endogenous UV-positivity in HSCs, a PE-coupled CD32 antibody 
(Invitrogen/molecular probes) for LSECs and an APC coupled F4/80 antibody for KCs (Life Technologies 
Corporation, Carlsbad, California, USA).
Mouse models of liver fibrosis. Male BALB/c mice (aged 9–10 weeks) were used. The experimental 
procedures were approved by the institutional Animal Care and Use Committee of the Vrije Universiteit 
Brussel, permit number 12-212-2, and National Institutes of Health principles of laboratory animal care 
(NIH publication 86–23, revised 1995) were followed.
Chronic liver injury was induced by repeated intraperitoneal injections of carbon tetrachloride (CCl4 
50 μ l /100 g body weight in mineral oil; both from Sigma) twice per week for 2 to 8 weeks or by common 
BDL (3–10 days). For common BDL, a peritoneal incision was made and the common bile duct was 
ligated and disrupted. Next, the abdominal cavity was closed with sutures and the animals were allowed 
to recover. At the end of the procedure, HSCs were isolated by FACS, based on UV-positivity. Isolated 
cells were not cultured, but immediately used for mRNA and miRNA analysis.
miRNA and mRNA isolation and analysis. Total RNA containing miRNA was purified from qHSC 
and aHSC samples using RNeasy MICROKit (QIAGEN GmbH, Hilden, Germany) following a deviation 
of the standard protocol as recommended by the manufacturer and using 1.5 volumes of 100% ethanol 
before applying the sample into the column. Total RNA concentration and quality control was assessed 
using the RNA 6000 pico kit (Agilent, Santa Clara, CA).
Taqman human miRNA Array (card A and B) (Applied Biosystems, Life Technologies Corporation, 
Carlsbad, California, USA) was used to profile the expression of 758 miRNAs in 4 quiescent and 4 acti-
vated HSCs by PCR amplification and real time analysis. Each miRNA array was used in conjunction 
with pre-defined pools of primers for each array (Megaplex™ RT Primers, Applied Biosystems). Due to 
the small quantity of starting material (30 ng each sample), miRNA cDNA samples were pre-amplified 
by PCR (Megaplex PreAmp Primers, Applied Biosystems) prior to loading on the array. The abundance 
of each miRNA in a total RNA sample was normalized to the level of the RNU6 expression (computa-
tion of –Δ Ct). Fold changes were computed from the means of each group and statistical significance 
was established at p ≤ 0.05 (student t-test). A total of 13 mRNA samples, 4 qHSC together with their 
respective activated HSC samples, 2 hepatocyte samples and 3 LSEC samples were analyzed for gene 
expression profiling using Affymetrix HG-U219 genechips (Affymetrix, Santa Clara, California, USA). 
Raw data are made publically available on the NCBI Gene Expression Omnibus database, with accession 
number GSE67664.
Integrative analysis of miRNA and mRNA expression data. In order to identify potential func-
tional interactions of miRNAs with their target genes, we integrated gene and miRNA expression pro-
files obtained from both miRNA and mRNA arrays by using miRComb-R package (http://mircomb.
sourceforge.net). This software package allowed us to identify potential relevant miRNAs regulating tar-
get genes differentially expressed in qHSCs by first identifying differentially expressed genes and microR-
NAs, secondly calculating significant microRNA and mRNA correlations and third screening databases 
for known and predicted miRNA-mRNA target pairs. The first step consisted in the identification of 
differentially expressed genes and miRNAs in qHSCs.
We defined highly enriched mRNAs in qHSCs or “qHSC specific” genes as those with at least two-fold 
higher expression when comparing qHSCs to hepatocytes and LSECs. In addition, we refined this col-
lection, by selecting only those mRNAs that are down-regulated upon HSC activation (FC qHSC vs 
aHSC ≥ 1.5).
Secondly, we classified mRNAs more highly expressed in aHSCs by using a cut-off of 2-fold higher 
expression than in hepatocytes and LSECs; again the number of genes in this category was reduced by 
selecting only those mRNAs that are significantly upregulated between qHSCs and aHSCs.
For the miRNAs we also used the 2-FC criteria for selecting those that are up-regulated during culture 
induced activation and a 1.5-FC cut-off was used for the miRNAs down-regulated during HSC activation.
In a second phase of the integration procedure we identified those miRNA-gene pairs showing neg-
ative correlation between miRNA and mRNAs. To accomplish this, Pearson correlation of the expres-
sions of all possible combinations of deregulated mRNAs vs deregulated miRNAs were computed. 
Multiple testing correction was performed in order to reduce the number of false positive correlations 
and a final cut-off was set to FDR (false discovery rate) < 0.05. Computed correlations are shown in 
Supplementary Figure 1. The third step in the integration procedure was to identify miRNA-mRNA 
pairs that were found to be predicted in the MicroCosm database. Basically, the package assigned a 
p-value to each miRNA-mRNA pairs according to the MicroCosm database (p_database) which predicts 
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mRNA-miRNA interactions based on miRNA and mRNA 3’UTR alignment sequences18. Finally, only 
those pairs with significant negative correlation (FDR < 0.05 and Pearson Coefficient < 0) and predicted 
by the MicroCosm database as potential target (p_database < 0.05) were selected as potential functional 
miRNA-mRNA interactions.
Quantitative real time PCR (miRNA and mRNA). Expression of mature miRNAs was assessed by 
reverse transcription using Mir-X miRNA First-strand Synthesis Kit (Takara, Dalian, China) according 
to the manufacturer’s instructions and qPCR reaction was performed by using SYBR® Advantage qPCR 
premix (Takara). mRNA levels were determined by quantitative real time PCR on an ABI 7900HT cycler 
(Applied Biosystems) using SYBR green master mix (Life technologies). Individual gene and miRNA 
expression was normalized to GAPDH or U6 expression, respectively. Relative expression was calculated 
using the comparative Ct method (2−ΔΔCt). Gene specific primers were produced by Integrated DNA 
Technologies (Leuven, Belgium). Primer sequences used are listed in Supplementary Table 3.
In vitro modulation of miRNA expression in human HSCs (LX2). In order to validate relevant 
miRNA-mRNA interactions resulting from the integrative analysis, miR-21 and miR-100 expression were 
knocked down and miR-192 was over-expressed in a human HSC cell line (LX2) (kindly provided by Dr. 
Friedman). LX2 cells were grown in DMEM containing 10% FBS at 37 °C with 5% CO2 and humidity. 
LX2 cells were transfected with 50 nM of mirVanaTM miRNA Inhibitor for miR-21 and miR-100 and 
mirVanaTM miRNA mimic for miR-192 (Life Technologies) using JetPRIME® (PolyPlus, Illkirch, France) 
according to the manufacturer’s recommendations. mirVanaTMmiRNA mimic and mirVanaTMmiRNA 
inhibitor negative control (Life Technologies) were used as a calibrator sample to evaluate miRNA and 
target gene relative expressions. 24 hours after transfection, cells were harvested and immediately used 
for miRNA and mRNA expression analysis.
Cell proliferation assay. Cell proliferation was assessed in mouse HSCs after 24 hours mimic miR-
192 transfection (Life Technologies). Cell proliferation was measured as active DNA synthesis with 
the Click-iT EdU Cell Proliferation Assay Kit (Invitrogen, Eugene, OR), following the manufacturer’s 
instructions as described before19. In brief, 7500 cells were seeded per cm2, 48 hours after miRNA mimic 
transfection cells were incubated with EdU for 48 hours prior to fixation and staining of the cells at day 
5 of the culture. The ratio of total cells and EdU-incorporated cells was calculated.
Cell migration assay. Cell migration of mouse primary HSCs was determined by a trans-well migra-
tion assay as described before20, using PDGF-BB (20 ng/ml) as a chemoattractant. In brief, cells were 
transfected with 50 nM miRNA mimic at day 5 and day 7 of the culture. At day 8, 100.000 cells were 
transferred to a collagen I-coated transwell chamber. One hour later, PDGF-BB was added to the lower 
compartment and cells were allowed to migrate for 18 hours.
Cell activation assay. Freshly isolated, primary mouse HSCs were seeded at a density of 15.000 cells/
cm2 and transfected with miR-192 or control mimic 24 h after plating. On day 2, transfected cells were 
serum-starved overnight and subsequently exposed to 10 ng/ml human recombinant TGFβ 1 (R&D) for 
48 h, prior to being lyzed for RNA extraction.
Statistical analysis. GraphPad Prism v4.0.0 (GraphPad Software, La Jolla, CA) and SPSS V.14.0 for 
Windows (SPSS Inc, Chicago, Illinois, USA) were used for statistical analysis. Data in the figures are 
expressed as means ± SEM. Differences among groups were tested for statistical significance by Student 
t-test or Mann Whitney U test when appropriate. Ns = not significant p ≥0.05, *p <0.05, **p <0.01, 
***p < 0.001.
Results
Characterization of FACS-sorted human liver cell populations and culture activated 
HSCs. Human liver cells were isolated from healthy liver donors. Hepatocytes were isolated by enzy-
matic perfusion of the liver and low-speed centrifugation steps in two different donors. Enriched pop-
ulations of qHSCs (UV+CD32−CD45−) and LSECs (CD32+CD45−) were purified from the resulting 
non-parenchymal cell fraction by FACS-sorting. Moreover, qHSCs isolated by density gradient from 
the same patients were cultured until passage four to obtain pure populations of aHSCs. To assess the 
purity of the different cell populations we measured the expression of specific markers for each liver cell 
type. qHSC and LSEC sorted fractions were highly enriched in PDGFRB and CD32b respectively and no 
significant expression of albumin was detected (Fig. 1A). Purity and activation of the in vitro activated 
HSCs were assessed by measuring the expression levels of classical activation and quiescent markers in 
the non-purified non-parenchymal cell fraction (NPF), in the qHSC-enriched nycodenz fraction and 
in culture-activated HSCs (Fig. 1). Culture-activated HSCs expressed PDGFRB but not CD32b or F4/80 
indicating the absence of contaminating LSECs and KCs respectively. In addition, aHSCs expressed high 
levels of the classical activation markers ACTA2, COL1A1 and LOX and low expression levels of SPARCL1 
and ATP1B2 compared to non-parenchymal cells and the qHSC enriched nycodenz fraction (Fig. 1B).
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MiRNA profiling of human quiescent HSCs. In order to determine the miRNA expression profile 
of qHSCs we compared the expression levels of 758 miRNAs in four qHSC samples and their corre-
sponding in vitro activated cells. Surprisingly, among the differentially expressed miRNAs only 47 (18%) 
were found to be highly expressed in qHSCs and significantly down regulated upon in vitro activation 
(p < 0.05). In contrast, 212 (82%) miRNAs barely expressed in qHSCs were significantly up-regulated 
during activation (Fig. 2). The top significantly up-regulated miRNAs upon activation are summarized 
in Supplementary Table 4.
Integrative miRNA-mRNA expression analysis. To identify deregulated miRNAs with a potential 
role during HSC activation we assessed miRNA expression profiles in the context of the expression of 
their target genes (Fig. 3A). Integration of miRNA and gene expression profiles from human qHSCs and 
aHSCs revealed a set of miRNAs that negatively correlated with the expression of their predicted target 
genes. Interestingly, when we plot the differentially expressed miRNAs with the number of their differen-
tially expressed predicted target genes we observed that the miRNAs expressed in qHSCs cluster together 
due to the large number of potentially regulated target genes (Fig. 3B). In contrast, the integrative anal-
ysis assigned a smaller number of target genes to the miRNAs up-regulated in the activated phenotype 
(Fig. 3B). Indeed, 66% of miRNAs expressed in qHSCs were associated with at least 6 target genes with 
an average of 17,28 ± 10,7 target genes per miRNA, whereas we did not find any miRNA up regulated 
in aHSCs with more than 4 predicted targets except for miR-100 (Fig.  3B). Activated HSC-associated 
miRNAs had an average of 1,49 ± 0,7 target genes. These results indicate that a relatively small number of 
miRNAs potentially regulates an important number of genes in qHSCs, while the opposite (a large num-
ber of miRNAs each of them regulating a small number of genes) may be taking place in activated cells.
In order to investigate whether miRNAs expressed in qHSCs were targeting/inhibiting the activation 
process we performed an in silico functional analysis with Ingenuity Pathway Analysis® software. As we 
expected, the interaction networks generated with genes targeted by miRNAs expressed in qHSCs were 
significantly related to key activation processes such as cellular movement, growth and proliferation as 
well as cell morphology. Moreover, hepatic fibrosis and HSC activation (p-value = 4.36·10−6) as well as 
actin cytoskeleton signaling (p-value = 0.017) pathways were found enriched in this set of target genes. 
These results indicate that qHSCs express a set of miRNAs that may be responsible, at least in part, for 
maintaining the quiescent phenotype by repressing genes involved in HSC activation. Table  1 shows 
Figure 1. Purity of sorted cell populations and cultured hepatic stellate cells: (A) Relative expression of 
hepatocyte (albumin), HSC (PDGFRB) and LSEC (CD32b) markers in qHSC, LSEC and hepatocyte samples 
(n = 3; each group). (B) Relative expression of liver cell markers (PDGFRB , CD32b and F4/80), activation 
markers (ACTA2, COL1A1, and LOX) together with quiescent markers (SPARCL1, ATP1B2) in non-
parenchymal fraction (NFP), nycodenz qHSC fraction (NYCO) and aHSCs (passage 4).
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the miRNAs that are highly expressed in quiescent HSCs and have a high number (n > 6) of predicted 
target genes.
Figure 2. MiRNA expression profile of human quiescent HSCs. Heat map showing the differentially 
expressed miRNAs in freshly isolated qHSCs compared to their respective culture-activated HSCs (n = 4 
each group). miRNA expression data was generated by performing Taqman human miRNA Array. The 
intensity of each colour indicates the standardized ratio between intensity and the average expression of each 
miRNA across all samples. Red colour pixels indicate an increased abundance of miRNA in the indicated 
samples whereas green pixels indicate decreased miRNA levels in Log2 scale. The top miRNAs significantly 
deregulated in human quiescent compared to in vitro activated HSC are summarized in the table.
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Expression of miRNAs in human liver tissue. Although HSCs are the major cell type responsi-
ble for liver fibrogenesis, they represent only 8% of the total liver cells. In order to explore if miRNAs 
dysregulated in HSCs could be detected in human liver we assessed the expression of selected miRNAs 
in cirrhotic (n = 15) and healthy (n = 14) human liver tissues. MiR-192 was found significantly down 
regulated (relative expression of 0.68, fold change = −1.47) in cirrhotic livers compared to healthy livers 
indicating that this miRNA, which we have identified as highly expressed in qHSC by the miRNA array, 
could also be detected in healthy tissue (Fig. 4A). On the other hand, miR-125b-1* and miR-21 signifi-
cantly increase their expression in cirrhotic liver compared to healthy tissue (fold change = 2.2 and 5.6, 
respectively) (Fig. 4B).
Figure 3. MiRNA-mRNA integrative analysis. (A) miRNA-mRNA integration analysis workflow. The 
diagram shows the reduction of the potential mRNA targets for miR-192 achieved by integrating miRNA 
and gene expression data: first, miR-192 is connected with its targets predicted by the Microcosm database; 
second, miR-192 is connected with its targets predicted by Microcosm and also found deregulated during 
activation of human HSCs (p < 0.01) and finally, the functionally relevant miR-192 targets based on 
significant negative correlation between miR-192 and its predicted targets and the MicroCosm prediction 
value is shown (B) Histogram representing differentially expressed miRNAs according to the number of 
deregulated target genes assigned by miRNA-gene integration analysis (p < 0.01). Red bars indicate miRNAs 
highly expressed in qHSCs whereas green bars show miRNAs highly expressed in activated HSC.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:11549 | DOi: 10.1038/srep11549
In vitro modulation of miR-192 in activated human HSCs. MiR-192 has a high number of pre-
dicted target genes (n = 28) in qHSCs, displays a significant reduction in expression between healthy and 
cirrhotic human liver tissue and it has not been previously reported to be associated with HSC or liver 
fibrosis. For those reasons, we selected miR-192 for further functional characterization by modulating its 
expression in human and mouse HSCs (Figs 5 and 6). As a control miRNA we used miR-100 and miR-21. 
MiR-100 is the up-regulated miRNA following HSC activation and has the highest number of predicted 
targets and miR-21 is not only up-regulated in activated HSC but also in human cirrhotic tissue.
As expected, by increasing the expression levels of miR-192 we observed a significant reduction in 
the expression of its target genes, PLAU and COL5A1, as well as a modest but significant reduction 
of the activation marker LOX and an increase in SPARCL1, a novel quiescence marker identified in 
the gene expression array. On the contrary, an inhibition of the endogenous miR-100 expression level 
enhanced the expression of its two predicted target genes, i.e. BTG2 and SPARCL1, but also caused a 
~20% reduction of the basal expression of pro-fibrogenic genes such as COL1A1 and LOX. Accordingly, 
miR-21 inhibition resulted in the reduction of miR-21 target genes expression (BTG2 and SPRY1) and 
also in a significant decrease of ACTA2 (Fig. 5A,B). Altogether, these results validate the computational 
integrative analysis and on the other hand they confirm the role of these microRNAs as regulators of the 
aHSC phenotype by modulating the expression of activation markers.
Quiescent miRNAs
miRNA
FC (Q vs. 
A) p-value
#target 
genes
miR-200b 22,55 0,0006 45
miR-200a 12,8 0,0029 38
miR-548b-5p 10,03 0,0068 35
miR-223 5643,5 2.06·10–5 32
miR-489 50,55 0,008 31
miR-363 20,82 0,0025 29
miR-142-3p 941,7 0,0002 28
miR-192 8,53 0,0107 28
miR-135a 11,09 0,0031 27
miR-126 32,08 0,0098 23
miR-142-5p 387,72 0,001 23
miR-202 91,63 0,0218 23
miR-628-5p 14,28 0,0113 23
miR-375 153,42 0,0006 21
miR-522 17,14 0,0143 21
miR-150 870 0,0001 20
miR-429 27,76 0,0493 20
miR-126* 64,65 0,004 19
miR-885-5p 780,16 4,34·10–6 19
miR-139-3p 33,47 0,0029 16
miR-302c* 32,21 0,0238 16
miR-139-5p 63,82 0,0069 15
miR-605 12,08 0,0127 15
miR-372 100,85 0,0149 12
miR-342-5p 17,53 0,0007 10
miR-520d-3p 8,37 0,0271 9
miR-572 26,23 0,0069 9
miR-483-5p 259,55 0,0023 8
miR-504 120,82 0,0011 8
miR-639 16,27 0,0197 8
miR-519a 15,4 0,0381 7
Table 1.  Panel of miRNAs enriched in qHSCs with the number of deregulated predicted target genes.
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MiR-192 is highly expressed in qHSCs and might play a functional role in suppressing HSC 
activation. Next, to understand the dynamics of miR-192 expression during HSC activation, we used 
HSCs isolated from mouse livers. MiR-192 expression was evaluated in HSCs isolated at different time 
points from two different fibrotic mouse models: bile duct ligation surgery (BDL) and chronic CCl4 
administration. Interestingly, miR-192 expression in HSCs was clearly reduced during fibrogenesis at 
very early time points in both animal models indicating that down-regulation of miR-192 in HSCs 
might be an early event during HSC activation and fibrogenesis (Fig. 6A). In order to identify other cells 
producing miR-192 in the healthy liver, miR-192 expression was assessed in freshly isolated hepatic cell 
populations (i.e. hepatocytes, KCs, LSECs and qHSC) from healthy mouse livers. Our results indicate that 
qHSCs are the major source of miR-192 expression in the healthy liver and that the expression of this 
miRNA in HSCs is lost upon culture-induced and in vivo activation (Fig.  6B). Additionally, we aimed 
to explore whether the level of miR-192 functionally contributed to the reduction of HSC activation 
(Fig. 6C). We first evaluated the effect of miR-192 in primary mouse qHSCs. Importantly, miR-192 over-
expression clearly inhibited the TGFβ 1-induced activation of qHSCs as measured by the suppression of 
Acta2, Col1a1 and Lox expression, three key early activation markers in HSCs (Fig. 6C). Next we tested 
if miR-192 was able to repress functional activation features. Transfection of primary mouse aHSCs with 
miR-192 mimics showed a marked (42.7 ± 0.11%) reduction in cell proliferation compared to cells that 
were transfected with the control mimic. Consistent with this result, PDGF-induced migration of mouse 
HSCs was reduced by miR-192 transfection (Fig. 6C). Taken together these results suggest that miR-192 
is a qHSC enriched miRNA in the liver with a functional role during HSC activation.
Discussion
In the present study we provide the first miRNA expression profile in human HSCs. Moreover, to iden-
tify key miRNAs involved in the maintenance of the quiescent phenotype and explore the pathways that 
might be regulated by miRNA, we have combined gene and miRNA expression data from human qHSCs 
and from corresponding aHSCs. Our study identified a reduced panel of miRNAs highly expressed in 
qHSCs which are predicted to target a high number of genes known to be involved in the activation 
Figure 4. MiRNA expression levels in cirrhotic and healthy human livers. (A) Expression levels of qHSC 
enriched miRNAs in cirrhotic (n = 14) and healthy (n = 15) human liver samples. (B) Expression levels of 
aHSC enriched miRNAs in cirrhotic (n = 15) and healthy (n = 14) human liver samples.
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Figure 5. In vitro modulation of miRNA-21, miRNA-100 and miRNA-192 expression in LX2 cells. 
Reduction of miR-21 and miR-100 expression and up-regulation of miR-192 in LX2 cells was achieved 
by transfecting miR-21 antagomir (50 nM), miR-100 antagomir (50 nM) or miR-192 mimic (50 nM), 
respectively (n = 3). (A) Box plots show the significant negative correlation between miRNA and target gene 
expressions. MiR-21 and miR-100 inhibition causes an increase of the expression levels of their target genes 
while miR-192 overexpression decreases target gene expression levels (B) In vitro modulation of miR-21, 
miR-100 and miR-192 expression result in a reduction of HSC activation.
process. Moreover, this study provides basic information on miRNAs in HSCs and forms the basis for 
further studies deciphering the role of miRNAs in liver fibrosis.
HSCs have been extensively studied due to their important role during liver fibrogenesis21–23. However, 
most studies have been performed with rodent HSCs and human information is still limited. Studies on 
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Figure 6. Expression and function of miR-192 in primary mouse HSCs. (A) Expression of miR-192 
in mouse HSCs during in vivo activation. Mir-192 expression levels were assessed in HSCs isolated from 
control mice, mice treated with CCl4 and from mice after BDL- or sham-operation at indicated time points 
after treatment or surgery. miRNA expression is shown relative to control or sham operated mice. (B) 
miR-192 expression in different hepatic cell types isolated from healthy mouse livers. MiR-192 expression 
was evaluated by qPCR in hepatocytes, quiescent and in vitro activated HSCs, KCs and LSECs. Mir-
192 expression is shown relative to whole liver (C) Effect of miR-192 over-expression on cell activation, 
migration and proliferation in primary mouse HSCs. The contribution of miR-192 to HSC proliferation was 
evaluated in transfected mouse HSCs 1 day after miR-192 mimic transfection. HSCs were exposed to EdU, 
fixed 2 days later and stained for DNA-incorporated EdU. Proliferation is represented by the percentage of 
EdU-positive cells. Contribution of miR-192 on mouse HSC migration was assessed by a transwell migration 
assay on primary mouse HSCs transfected with mimic miR-192. PDGFbb (20 ng/mL) was added to promote 
cell migration. After 18 hours migrated cells were stained with DAPI and counted. Results are represented 
as migration relative to the non-PDGF stimulated cells. Finally, the effect of overexpressing miR-192 on 
cell activation was evaluated by exposing freshly isolated mice HSCs to TGFβ 1 (10 ng/mL) or solvent for 
48 hours. Results are represented as relative expression to miR control incubated with solvent.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 5:11549 | DOi: 10.1038/srep11549
qHSCs have been hampered by the lack of good methods to maintain HSCs quiescent in culture, even for 
a short period of time. Indeed, a number of studies have shown that the gene expression pattern of HSCs 
is altered after a few hours in culture24. Actually, culture-activated human HSCs acquire a phenotype that, 
although not identical, resembles the activation state of HSCs in the fibrotic liver25. In this study we have 
assessed the gene and miRNA expression profile of freshly un-cultured human qHSCs. Cells were iso-
lated through cell sorting by both immunoselection and UV auto-fluorescence. It is important to notice 
the novelty of this procedure, since it varies substantially in terms of isolation conditions and phenotype 
of the cells from already described procedures with mouse cells using FACS sorting approaches19,26. To 
be able to identify which miRNAs changed their expression during cell activation, miRNA and gene 
expression profiling was performed in cells activated in vitro from the same individuals from which 
quiescent cells were isolated. The use of culture-activated HSCs allowed us to minimize the variability 
existing among patients with chronic liver diseases due to etiology, stage of disease development or 
sample collection procedure.
The expression level of a miRNA provides limited information about its role. miRNAs are non-coding 
regulators of gene expression and therefore, their role depends on their level of expression but also the 
expression of their target genes27,28. Since the role of a miRNA can only be defined if we know its spa-
tiotemporal coexistence with its target mRNA, it was important to assess the miRNA expression profile 
in the context of the expression of their target genes in both human qHSCs and aHSCs. Moreover, we 
have used the miRComb-R package, an integrative bioinformatics tool, able to predict potential biolog-
ically relevant miRNA-mRNA interactions based on both miRNA-mRNA expression correlations and 
sequence hybridization predicted in well-known databases12,29. This integrative approach allowed us to 
identify miRNAs not previously associated with HSC biology, but also to identify new targets for miR-
NAs already described to play a role in HSCs and fibrosis.
An interesting observation of the present study is the consistent up-regulation of miRNAs during in 
vitro HSC activation. Actually, approximately 80% of the differentially expressed miRNAs (212/259) were 
found expressed at low levels in the qHSCs and up-regulated in aHSCs. By contrast, the transcriptome 
analysis showed a more balanced ratio of up and down-regulated genes during activation. In order to 
understand the relevance of these findings, we merged the miRNA and gene expression profiles to reveal 
the potential miRNA-target interactions.
One of the most important findings of this study is the higher number of target genes assigned by the 
computational integrative analysis to miRNAs expressed in quiescent cells compared to those measured 
in their activated counterparts. Importantly, miRNAs expressed in qHSCs targeted genes involved in 
HSC activation and liver fibrosis such as different collagen types (COL5A1,COL4A5, COL8A1, COL9A3), 
LOX, TGFβ or IL-61,20,30. These results were further supported by the in silico functional analysis of these 
targeted mRNAs showing their association with important pathways regulating HSC activation. These 
results may indicate that miRNAs highly expressed in qHSCs could be acting as suppressors of HSC 
activation, thereby preventing HSC activation towards myofibroblast-like cells. This would suggest that 
HSC quiescence is an actively maintained state. This finding has a potential physiological and clinical 
relevance as it suggests that strategies aiming at preventing HSC activation could be based on mimicking 
the function of these miRNAs expressed in qHSCs.
Among all miRNAs expressed in qHSCs, we have highlighted a subset of 31 miRNAs which are tar-
geting/inhibiting more than 6 up-regulated genes during activation. It is important to notice that these 31 
miRNAs are targeting 27% (267 out of 998) of all up-regulated genes during activation and some of these 
miRNAs have been previously reported to be associated with activation of HSCs. For instance, miR-150 
has been shown to be down-regulated in HSCs isolated from rat fibrotic livers12, while expression of miR-
126 and miR-126* were reduced during in vitro and in vivo activation of rat HSCs31. Other miRNAs such 
as miR-192, miR-139-5p, miR-483-5p, miR-142-3p, miR-142-5p, or miR-375 have not been previously 
described to be expressed in HSCs.
Among all miRNAs identified in qHSCs, miR-192 was selected for further functional assays in human 
and murine HSCs. The selection was based on its enrichment in quiescent HSC and healthy liver tissue, 
the high number of predicted targets, the loss of expression in cirrhotic patients as well as the novelty 
of miR-192 in the context of liver fibrosis. We first studied whether miR-192 could be considered as a 
quiescent-specific miRNA during both in vitro and in vivo activation. As found in human, HSCs derived 
from healthy mice presented significant higher levels of miR-192 compared to the HSCs isolated from 
fibrotic mice and its expression was rapidly reduced upon induction of fibrosis in vivo. In the present 
study, we also provide evidence for the role of miR-192 in the regulation of HSC activation by showing 
that overexpression of miR-192 suppresses TGFβ 1-induced up-regulation of classical activation genes, 
i.e. Acta2, Col1a1 and Lox. Additionally, we find that miR-192 overexpression significantly repressed the 
proliferation and migratory potential of primary mouse HSCs, both key functional properties acquired 
during HSC activation. Moreover, miR-192 mimics reduced the expression of key activation markers in 
a human HSC cell line. Although the modulation of individual activation markers by miR-192 mimic 
may be modest, we provide evidence that miR-192 has a functional effect on HSCs. Particularly, these 
findings indicate that miR-192 can actively promote a quiescent phenotype in fibrogenic conditions and 
suggest potential therapeutic value for the modulation of miR-192 expression.
Our data also provides information regarding the miRNAs that may be playing a role during HSC 
activation. Interestingly, the bioinformatic analysis assigned a small number of targets to the miRNAs 
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up-regulated in activated state. Among all miRNAs found highly expressed in aHSCs, miR-100 is the 
miRNA with the highest number of predicted target genes. Interestingly, according to the mRNA-miRNA 
integrative analysis performed, SPARCL1-like (SPARCL1) is the gene that is targeted by the highest num-
ber of miRNAs (10 miRNAs up-regulated in aHSC are predicted to target SPARCL1) (Supplementary 
Table 5). Moreover, when we analyzed the transcriptomic data obtained by comparing activated vs quies-
cent HSC gene expression we found that SPARCL1 was strongly (fold change = − 40) downregulated dur-
ing HSC activation and this infra-expression was also validated by qPCR. SPARCL1 is a protein member 
of the matricellular SPARC family of proteins, a diverse group of proteins that modulate cell interaction 
with the extracellular milieu. SPARCL1 is the only SPARC family member, in addition to SPARC itself, 
which can bind to fibrilar collagens and influence collagen fibril architecture32,33. In concordance with 
the integrative analysis, functional in vitro assays showed that mir-100 inhibition resulted in SPARCL1 
up-regulation and in a significant reduction of COL1A1 and LOX expression levels.
In conclusion, by integrating miRNA and mRNA expression data obtained from quiescent and acti-
vated human HSCs we have identified a panel of miRNAs highly expressed in qHSCs compared to 
aHSCs. These miRNAs are predicted to target over 25% of all up-regulated genes following HSC acti-
vation and therefore might have a common functional role in repressing HSC activation. Among all 
miRNAs included in this panel we have shown that miR-192 is down-regulated both during in vivo and 
in vitro activation of qHSCs and that overexpression of miR-192 exerts a functional role during the acti-
vation program by reducing activation, migration and proliferation of HSCs. Further studies are needed 
to evaluate whether the identified miRNAs have a coordinated functional role in the maintenance of the 
quiescent phenotype and the repression of HSC activation.
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